August 05, 2022 07:30 ET | Source: Arch Biopartners TORONTO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company targeting acute organ inflammation with novel therapeutics, announced today that the Company has added Dr. David Luke as a Strategic Advisor for the clinical trial development of the Company’s drug candidates. Dr. Luke previously held a variety of positions in the pharma industry, including approximately twenty years at Pfizer Inc, where he was a Senior Medical Director, ...
Full Release

TORONTO, Feb. 24, 2022  — Arch Biopartners Inc. (“Arch Biopartners”, “Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today that it has been named to the 2022 TMX Venture 50 List of Top Performing TSX Venture Exchange Companies as one of the top 10 companies in the category “Clean Technology and Life Sciences”.  Februrary 24, 2022 Arch Biopartners CEO, Richard Muruve interview with TMX Markets "We are honoured today to shine ...
Full Release

LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys common in several indications, including moderate to severe cases of COVID-19, regardless of variant type. TORONTO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch Biopartners”, “Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today that Health Canada has approved the amendment to the CATCO protocol to include its lead drug candidate, ...
Full Release